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DEDICATION

This research work is dedicated to all the patients afflicted with Inflammatory
Bowel Disease (ulcerative colitis), their physicians, and researchers who are in
pursuit of identifying better ways of treating this chronic debilitating illness.
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ABSTRACT

The aim of this study was to determine which symptom domains in
ulcerative colitis (UC) are important in the evaluation of disease activity. An
important symptom is that which 1) occurs during flares, 2) improves during
effective therapy, and 3) resolves during remission. Twenty eight symptom
domains were evaluated. Sixty subjects were surveyed, rating each symptom on
three criteria with a 100 mm Visual Analog Scale (VAS). Important symptoms
were defined a priori as those whose median VAS rating for all 3 criteria was
significantly greater than 50. Thirteen of the 28 symptom domains proved to be
both frequent in UC flares and responsive to changes in disease activity. Seven
of these were novel symptoms derived from UC patient focus groups.
In conclusion, development of survey measures of these symptom
domains could significantly improve the assessment of disease activity in UC.
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CHAPTER 1: INTRODUCTION
Ulcerative colitis (UC) is a chronic inflammatory disease that affects more
than 600,000 Americans (Loftus, 2004). Flares of UC typically result in
inflammation of the affected portion of the gastrointestinal tract with symptoms
that include frequent diarrhea, urgent bowel movements, and rectal bleeding
(Baumgart & Sandborn, 2007; Sands, 2007). Uncontrolled inflammation can
result in toxic megacolon and perforation, which has a mortality rate of 40%
(Berg et al., 2002). Controlling inflammation and therefore symptoms is the
primary goal of treatment, but current therapies are only moderately effective, as
27-45% of patients eventually need total colectomy (Leijonmarck et al., 1990;
Turner et al., 2007). Hundreds of potential new therapies are in preclinical
testing, including molecules targeting CD3, IL12p40, and IL17, and many are
expected to be evaluated in clinical trials in humans.
The efficacy of therapies in UC is assessed with disease activity indices,
which typically combine clinical symptoms, physician assessment, and invasive
endoscopy to measure severity (Schroeder et al., 1987; Sutherland et al., 1987).
Yet there exists no consensus gold standard to evaluate the efficacy of these
treatments for UC. There are a number of indices that attempt to measure
disease activity in ulcerative colitis, including the Mayo Index (Schroeder et al.,
1987), the UCDAI (Sutherland et al., 1987), the Seo Index (Seo et al., 1992), the
Ulcerative Colitis Clinical Score (Feagan et al., 2005), the Simple Clinical Colitis
Activity Index Walmsley et al., 1998), and the St. Mark’s Index (Powell-Tuck et
al., 1978). Notably, it has never been established that any of these indices
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actually measures all of the important components of ulcerative colitis. Most
current indices were developed without patient input, and items were not tested
for their responsiveness to change. The lack of a patient-centered index raises
the question of whether the indices truly capture all of the symptoms that occur
during a flare for patients with UC.
Previously, focus group interviews were conducted with UC patients who
discussed their UC experience and how their symptoms related to periods of
flare or remission. We recorded and qualitatively analyzed all signs and
symptoms discussed during these group interviews and compared our findings
with existing index components (Waljee et al., 2007). We concluded that current
indices capture only a portion of clinical symptoms and include several symptoms
not identified by patients. In addition, patients identified new symptoms not
previously assessed in UC disease activity indices. As a result, it is believed that
current indices may not completely measure or reflect patients’ experience of
UC.
The current lack of a patient-centered index and the numerous candidate
therapies in developmental stages highlight the need to develop a new disease
activity tool for clinical research that is patient-centered and validated and that
will provide a rigorous benchmark for determining clinical efficacy of new UC
therapies. An ideal index for the measurement of disease activity in UC would
include the symptom domains important to patients and would focus on
symptoms that occur in most patients and are responsive to changes in disease
activity (have a good dynamic range). Symptom domains that are responsive to
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changes in disease activity would reproducibly worsen during flares, improve with
effective therapy, and be absent during remission. This study chose to evaluate
16 symptom domains from currently existing UC disease activity indices as well
as 12 novel symptom domains identified in our previous focus group study
(Waljee et al., 2007). All of these 28 symptom domains were identified as
important by at least one patient with ulcerative colitis in our focus groups. The
aim was to quantitatively determine which symptom domains would be most
useful for inclusion in the development of a new patient-centered UC disease
activity index by evaluating their frequency and responsiveness to change in
patients with ulcerative colitis.
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CHAPTER 2: REVIEW OF RELATED LITERATURE
Ulcerative colitis adversely affects the quality of life of many Americans (Loftus,
2004), with symptoms that include frequent diarrhea, urgent bowel movements,
rectal bleeding, abdominal pain, and fatigue. Patients’ quality of life (Cohen,
2002) and economic productivity (Longobardi et al., 2003) are significantly
impaired by chronic ulcerative colitis. This disease often strikes individuals in
their teens and twenties, and continues to wax and wane for the remainder of
their lives. The severity of the symptoms, as well as the unpredictability of flares
of disease, can significantly impair the lives of those affected (Casellas et al.,
2002).
Current therapies for ulcerative colitis are only modestly effective, as up to
30% of patients eventually have total surgical removal of the colon. This is a
daunting and irreversible choice for young patients to make and is particularly
difficult for young females, in whom the scarring of the pelvic organs after total
colectomy can result in infertility rates of up to 40% (Gorgun et al., 2004;
Johnson et al., 2004). Therefore it is quite important to identify new medical
therapies that can control disease activity and maintain remission in patients.
Numerous cytokines and components of the immune system have been
therapeutically targeted in animal studies and preliminary human studies of
treatment of colitis. These include interleukin-1, interleukin-10, tumor necrosis
factor alpha, CD3, and many others. Other approaches have included removal of
activated monocytes and granulocytes, infusion of antibodies to important
adhesion molecules, enemas with growth factors to promote healing, and
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infusion of antisense RNA to adhesion molecules. Many of these therapies are
now in development for future human use and need to be rigorously evaluated
for their clinical efficacy. This research will develop a new validated tool for
clinical research that will provide a rigorous benchmark for clinical efficacy.
There is no gold standard for the evaluation of disease activity in
ulcerative colitis. This is illustrated in numerous recent clinical trials, in which
investigators measured several different indices of disease activity, since no one
index is considered sufficient. Among the many indices for the measurement of
ulcerative colitis disease activity, the first was Truelove and Witt’s classification of
mild, moderate, and severe disease (Truelove & Witts, 1955). This scale did not
include the possibility of remission, which likely occurred because corticosteroids
had never been used for ulcerative colitis when this classification was created.
This classification was converted into a point scale by Powell-Tuck, the St.
Mark’s Index, in 1978, when endoscopy was empirically added to the scale
(Powell-Tuck et al., 1978). This first index was never tested for validity,
reproducibility, or responsiveness. However, its application became common,
and the addition of endoscopy remained unquestioned. In practical terms,
however, the St. Mark’s index was cumbersome, and this led to numerous
simplified versions, including the Ulcerative Colitis Disease Activity Index and the
Mayo Score (Schroeder et al., 1987; Sutherland et al., 1987). None of these were
ever validated, had validated definitions of remission or improvement, nor had
even been compared to the St. Mark’s Index. Their convenience and simplicity
led to their rapid adoption and use. Eventually, regulatory authorities were faced
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with this confusing collection of indices when asked to approve new medications.
In response, the FDA asked a panel of experts to create an empiric
definition of remission for regulatory purposes, which was defined as a score of 1
or 2 on the Baron endoscopic scale (normal or only mild friability) and the
absence of patient-reported blood in the stool. This definition was also not tested
or validated, but it has become a standard for the approval of new medications
for ulcerative colitis and has driven an increase in endoscopy in clinical trials for
ulcerative colitis. Conceptually, mucosal healing as part of a definition of
remission in ulcerative colitis is very appealing. Ulcerative colitis is believed to be
due in part to abnormal interactions between the gut associated immune system
and intestinal bacteria, and damage to the mucosal barrier would seem to be an
important intermediate endpoint. However, obtaining data on the colonic mucosa
is invasive and costly. Several recent studies have suggested that mucosal
healing can be accurately predicted by noninvasive means with survey items and
biomarker (Seo et al., 2002; Higgins et al., 2005; Azzolini et al., 2005). Further
studies that compared stool biomarkers to endoscopic activity showed that the
biomarkers predicted endoscopic findings quite accurately (Kane et al., 2003;
Roseth et al., 2004).
The difficulty and costs of the standard invasive indices led to a desire for
less invasive indices of disease activity, and Seo in Japan and Walmsley in the
United Kingdom devised non-invasive disease activity indices. The Seo Index
used symptoms and laboratory tests to create a score that would parallel
Truelove and Witts’ categories of disease severity (Seo et al., 1992). Seo found
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that his index did predict the Truelove and Witts’ indices well and predicted which
patients would need colectomy (Seo et al 2002; Seo et al., 1995). Walmsley
devised a survey index, the Simple Clinical Colitis Activity Index (SCCAI) for use
in clinic encounters, which correlated quite well to the St. Mark’s Index and the
Seo Index (Walmsley et al., 1998). More recently, Jowett showed that the SCCAI
could predict clinician-defined relapse if a SCCAI score of > 5 points occurred
(Jowett et al., 2003). This ability to predict important clinical endpoints suggested
that the noninvasive indices had some clinical validity, but the necessity of
endoscopy for regulatory approval meant that few investigators used these
noninvasive indices. The absence of formal validation of any of the indices used
to measure disease activity, and the absence of any formal testing of the validity
of the criteria for regulatory remission, puts the assessment of any new therapies
for ulcerative colitis on very shaky ground. It has never been established that any
of these indices actually measures all of the important components of ulcerative
colitis, is reproducible, or is responsive to change in disease activity.
The current indices for ulcerative colitis are not validated, and the
regulatory definition of remission is a similar empiric non-validated approach.
Mucosal healing is only an intermediate endpoint and is not a direct measure of
patient health. The goal of disease activity indices in clinical trials is to take the
most accurate snapshot of disease activity possible at a given point in time.
While biomarkers and mucosal healing are appealing objective surrogate
endpoints, they serve us badly if they do not actually predict the health of
patients. It is important to be able to determine whether these and other markers
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of disease activity do actually correlate with patients’ disease status and are not
redundant and therefore provide unique additional information in a multivariate
model of disease activity. This will be accomplished in the proposed research.
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CHAPTER 3: RESEARCH DESIGN AND METHODOLOGY
Subjects
This study was undertaken at the University of Michigan Medical Center.
On a weekly basis, the University of Michigan Data Warehouse Team identified
all patients with a history of ulcerative colitis (UC) who had a scheduled
outpatient appointment to be seen at the University of Michigan. Patients were
identified as having a documented history of UC using the ICD-9 code of 556.x.
Inpatients with UC were also identified through regular consultation with the
inpatient gastroenterology service. Recruitment was performed face to face by a
study team member either in the outpatient setting (University of Michigan
Gastroenterology Clinic or endoscopy unit) or on the hospital inpatient service.
Inclusion criteria included age between 18 and 75 years, diagnosis of UC
as documented in the medical record, and willingness and ability to understand
and fill out the questionnaire. Exclusion criteria included a history of colectomy or
past participation in this study. The study was approved by the University of
Michigan Institutional Review Board and by the Eastern Michigan University
Human Subjects Review Board. A written informed consent was obtained from all
study participants prior to participation.
Questionnaire
A self-administered questionnaire was used to identify symptom domains
in UC that occur frequently during flares and are responsive to changes in
disease severity. Symptom domains were defined broadly as a symptom or sign
that could be used by the patient to assess his or her disease activity level.
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Enrolled study participants were given the symptom domain questionnaire to fill
out, and a study team member was present to answer any questions that arose.
The questionnaire consisted of three ratings of 28 symptom domains
found in UC. Sixteen of these symptom domains were from standard UC disease
activity indices (Schroeder et al., 1987; Sutherland et al., 1987; Seo et al., 1992;
Feagan et al., 2005; Walmsley et al., 1998). The remaining 12 symptom domains
were novel domains identified from focus group data (Waljee et al., 2007) (Figure
1). For each of the 28 symptom domains, participants were asked to rate the
symptom domain on three separate 100 mm visual analogue scales (VAS) for
each of the three endpoints: 1) the symptom is present during flares; 2) if present
during flares, the symptom improves with effective therapy; and 3) the symptom
is absent when in remission (Figure 2). Study participants were instructed to
mark the line at whatever point they felt was appropriate for that symptom
domain. Study participation was concluded upon successful completion of the
survey questionnaire.
Data Management and Statistical Analysis
Two study team members determined each symptom domain’s rating for
each of the three endpoints by independently measuring the distance in
millimeters from the left end of the VAS scale (0 mm) to the point where a mark
was made on the VAS scale line. Measurements were made using the same
ruler and to the nearest millimeter at the point where the mark crossed the VAS
scale line. The study team members independently entered these ratings, along
with demographic information, into a Microsoft Access (Microsoft Corporation,
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Redmond, WA) database. The Access datasets were imported into Epi Info v.
3.3.2 (Centers for Disease Control and Prevention, Atlanta, GA) to perform errorchecking. Any discrepancies in ratings for a given symptom domain endpoint
were resolved by having study team members re-examine the original
questionnaire and re-measure the VAS scale distance in contention. Consensus
was reached for all measurements. The final, corrected Access dataset was
imported into Stata 9.2 statistical software (Stata Corporation, College Station,
TX) for analysis.
The assumption was made that study participants who assigned a rating
of less than 20 mm to the first endpoint (“the symptom is present during flares”)
for a given symptom domain did not have that particular symptom domain
present during an active flare of their UC. Therefore, it was not possible for these
study participants to accurately assess the second endpoint (“if present during
flares, the symptom improves with effective therapy”) since therapy would not
have an affect on a symptom that was not originally present during flare. For
study participants in this situation, their rating for the second endpoint (improve
with therapy) was dropped from the dataset.
As the ratings for each of the three endpoints for the 28 symptom domains
were found to have a non-parametric distribution, medians and interquartile
ranges were calculated for all symptom domains for each endpoint for accurate
comparison. A nonparametric sign test was also performed to determine if the
medians for the endpoints were significantly greater than a cutoff of 50 mm on
the VAS scale. A two-sided p-value of <0.05 was used to determine statistical
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significance for this test. An important symptom domain was defined as one in
which ratings for all three VAS endpoints for that symptom domain are
significantly (two sided p <0.05) greater than 50 mm (see Figure 1). Symptom
domains in which any of the three endpoints were not significantly greater than
50 mm were considered not important.
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CHAPTER 4: PRESENTATION AND ANALYSES OF DATA
Patient Characteristics
A total of 60 UC patients were enrolled for participation in the study
between 2006 and 2007. The demographic and disease characteristics of the
enrolled study participants are presented in Table 1. The enrolled study
population had an essentially equal (31 males to 29 females) male/female ratio
and represented a broad range of the UC patient population at the investigators’
university-based institution. Disease location (proctitis, left-sided, pancolitis, or
unknown) was determined by asking the patient if they knew the extent of their
disease. Questionable or unknown disease extent was then verified in the
medical record from either a recent clinic note or colonoscopy report by the
patient’s gastroenterologist. Disease severity (quiescent, mild, moderate, severe,
or unknown) was determined through consultation with the patient’s
gastroenterologist at the time of their participation in the study.
Incidence of Symptom Domains that Are Frequent or Responsive
Many (17 of 28) symptom domains were found to be frequently present
during a UC flare, as they had a median VAS rating greater 50 mm for our first
endpoint (Figure 3). Likewise, a majority of symptoms (27 of 28, or all except for
mouth ulcers) were shown to improve with therapy more than half of the time, as
they also had a median VAS rating greater than 50 mm for the second endpoint
(Figure 4). In addition, all 28 symptom domains were found to be absent in
remission the majority of the time in most individuals (median VAS rating greater
than 50 mm for the third endpoint) (Figure 5). However, the criteria for defining
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an important and responsive symptom domain specifically stated that all three
endpoints for a particular symptom domain had to have a median VAS rating that
was significantly (p<0.05) greater than 50 mm.
Symptoms Domains that are Frequent and Responsive to Change
Thirteen of the 28 symptom domains fulfilled the criteria of an important
symptom domain, defined as a median VAS rating for all three endpoints
significantly (p<0.05) greater than 50 mm. These symptom domains included
stool mucus, tenesmus, difficulty telling liquid stool from gas before evacuation,
fatigue, rapid post-prandial bowel movements, loud bowel sounds, flatulence,
loose stool consistency, stool blood, urgency, frequency, bowel movements
during the night, and abdominal pain (Table 2). Approximately half (6/13) of the
important symptom domains were derived from standard indices of UC disease
activity. However, the remaining important symptom domains (7 of 13, 54%)
were novel symptom domains elicited from previously conducted focus groups
(Waljee et al., 2007) that were not found in standard UC indices. These seven
symptom domains were stool mucus, teems, difficulty telling liquid stool from gas
before evacuation, fatigue, rapid post-prandial bowel movements, loud bowel
sounds, and flatulence.
To illustrate the results for a representative important symptom domain,
the findings for the symptom domain stool mucus are presented in Figure 6. In
this symptom domain, 48 of 60 individuals had a VAS rating greater than 50 mm
for the first endpoint (“present during flare”), 46 of 53 individuals had a VAS
rating greater than 50 mm for the second endpoint (“improved with therapy”), and
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56 of 60 had a VAS rating of greater than 50 mm for the third endpoint (“absent
in remission”). In the case of the second endpoint for stool mucus, seven
individuals were not included because the values for their first endpoint were less
than 20 mm (see Methods). As the median VAS ratings for each of the three
endpoints of the symptom domain stool mucus were all greater than 50 mm, this
is a representative example of a symptom domain that fulfilled our criteria for a
symptom that is frequently present and is responsive to change.
Uncommon or Unresponsive Symptom Domains
Fifteen of the 28 symptom domains did not fulfill the criteria of an
important symptom domain. These symptom domains are listed in Table 2.
Noteworthy among these 15 symptom domains were 10 symptom domains that
are commonly found in standard UC disease activity indices but were not found
to be important symptom domains in this study.
Anorexia was an example of a symptom domain that did not fulfill the
criteria. In the case of the symptom domain anorexia, 34 of 60 individuals had a
VAS rating greater than 50 mm for the first endpoint (“present during flare”), 39 of
47 individuals had a VAS rating greater than 50 mm for the second endpoint
(“improved with therapy”), and 55 of 60 individuals had a VAS rating of greater
than 50 mm for the third endpoint (“absent in remission”) (Figure 7). As in the
example with stool mucus, 13 individuals for the second endpoint in anorexia
were not included because their VAS ratings for the first endpoint in anorexia
were not greater than 20 mm (see Methods). As the medians of the three
endpoints for the symptom domain anorexia were not all significantly greater than
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50 by the sign test, this is an example of a symptom domain found on commonly
used indices that did not meet our criteria for an important symptom domain.
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CHAPTER 5: SUMMARY, CONCLUSIONS, INFERENCES, AND
RECOMMENDATIONS FOR FURTHER RESEARCH AND ACTION
Conventional assessment of disease activity in ulcerative colitis is done
using any one of a number of disease activity indices that measure various
symptoms and signs that have been deemed relevant by the designers of these
indices. For the most part, the symptoms and signs included in the various
indices were determined solely by physician scientists without patient input.
Therefore, it is quite possible that the symptoms included in the UC disease
activity indices by their designers may not include all of the symptoms that are
most important to patients in assessing their disease activity. In previous work by
our research group (Waljee et al., 2007), we identified, through ulcerative colitis
patient focus groups, a number of symptoms that are important to these patients
but that are not currently included in the measure of UC disease activity.
Subsequently, as a result of this research study, it was found that a number of
those symptoms identified in our focus group study occur frequently during flares
of UC and are responsive to changes in disease activity. This qualifies them as
important symptom domains according to our criteria. It was also determined that
while several symptoms derived from currently used UC disease activity indices
qualify by our definition as important symptom domains, many of the symptoms
currently measured in UC disease activity indices do not qualify.
The results of this study provide the opportunity to develop a UC disease
activity index that better incorporates all of the symptom domains that are
frequently present during flares and are responsive to changes in disease
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activity. Thirteen symptom domains were identified that met our criteria of an
important symptom that is frequently present during flare and responsive to
change. Noteworthy is the fact that 7 of these 13 symptoms are not included on
currently utilized disease activity indices for UC. In addition, 10 of the 15
symptom domains found not to fit our criteria of an important symptom domain
were obtained from currently used disease activity indices (Table 2).
This research study had several limitations. First, the study population had
a somewhat homogenous composition of patients seen at a major universityaffiliated medical center that may represent individuals with a more severe
ulcerative colitis disease course than those seen in the general patient
population. However, it would be expected that while there is some diversity of
symptoms present during flare for any given individual with ulcerative colitis, the
disease occurs in such away that there is bound to be much common overlap of
symptomology. In addition, the study sample consisted of 52 individuals from the
outpatient setting and only 8 individuals who were admitted as inpatients at the
time of their participation. Yet it is believed that this may not be a major limitation
as the majority of individuals afflicted with ulcerative colitis are treated on an
outpatient basis.
Second, while we sought to assess three endpoints for each symptom
domain, namely “present during flare,” “improves with therapy,” and “absent in
remission,” if a particular individual did not experience a certain symptom, then it
would not be possible to assign a VAS rating to the second endpoint, “improves
with therapy.” The study attempted to control for this using the method outlined in
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the Analysis section of Methods, but the possibility exists that this biased how a
study participant assigned VAS ratings for a given symptom domain. Future
investigations should offer an option where a study participant would be given an
option to indicate that they have never experienced a particular symptom and
therefore would not assign any VAS ratings.
It is possible that several of the symptoms that were identified as
important (found to be present during a flare of UC and responsive to change)
could in fact be concurrent irritable bowel syndrome (IBS) symptoms, not directly
related to inflammatory bowel disease activity (IBD). Post-inflammatory IBS
symptoms have been shown to be relatively common in patients with IBD
(Minderhoud et al., 2004) and it is possible that these IBS symptoms are in fact
what is being reported by participants in this study. Contrary to this view is the
recent report that IBS-related symptoms in IBD correlate with increased fecal
calprotectin levels, a biomarker of inflammatory activity. This suggests that
symptoms frequently attributed to IBS may indicate occult inflammation in UC
patients (Keohane et al., 2007).
The findings presented in this study are important because they provide
quantitative evidence that the additional symptoms identified in our previous work
with UC patient focus groups 13 are in fact reasonable choices for further
investigation into their utility as part of a new index to assess UC disease activity.
These symptoms identified in focus groups that were also found to be important
by our criteria have great value in particular since they were identified with
patient input. The importance of patient input in the development and validation
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of new disease activity markers cannot be overemphasized because it allows us
to capture a better picture of disease activity in patients with ulcerative colitis. In
addition, the finding that a number of symptoms used at this time in common UC
disease activity indices in fact rarely present in UC flares and/or less responsive
to change only furthers the point that at this time we may not be optimally
assessing a patient’s UC activity.
This quantitative research study is an additional step in the process to
develop a patient-centered assessment of disease activity in patients with UC
that will be an improvement upon currently available methods. Some of the novel
symptoms identified in the focus group interviews have now been shown to occur
frequently and be responsive to change. It is now possible to proceed in
developing survey questions to better capture all of the symptom domains that
relate to a patient’s experience of ulcerative colitis. It is expected that the future
combination of improved survey questions for UC assessment and biomarkers of
UC inflammation will result in better assessment of disease activity and therefore
better care for patients.
Overall Study Highlights
What is Current Knowledge?
• Ulcerative colitis disease activity is measured through symptoms and signs
selected by researchers without the input of patients.
• We do not know if these symptoms represent all of the important symptoms in
the measurement of disease activity in UC.
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• We do not know if all of the symptoms we currently measure are helpful in the
measurement of disease activity in ulcerative colitis.
What is New Here?
• Several novel symptoms previously obtained from UC patient focus groups
were found to be frequent during flares and responsive to changes in disease
activity.
• Several of the symptoms we currently measure in UC activity indices were
found to be either infrequent or unresponsive to changes in disease activity.
• Careful measurement of these common symptoms that are responsive to
changes in disease activity is likely to improve the future assessment of
ulcerative colitis disease activity.
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Table 1
Demographics and disease characteristics of 60 patients with ulcerative colitis
who completed questionnaires on ulcerative colitis symptoms.
Characteristics
Participants (n=60)
%
Gender
Male
31
51.7
Female
29
48.3
NIH Race
Caucasian
54
90.0
Asian or Pacific Islander
0
0.0
Black
3
5.0
American Indian /
1
1.7
Alaskan
Hispanic
1
1.7
Other
1
1.7
Median [range] age
39.4 [18.6-72.8]
(years)
Median [range] disease
5.0 [1-37]
duration (years)
1 missing
Disease location
Proctitis
4
6.7
Left-sided
26
43.3
Pancolitis
28
46.7
Unknown
2
3.3
Disease Severity
Quiescent
3
5.0
Mild
24
40.0
Moderate
19
31.7
Severe
13
21.7
Unknown
1
1.7
Medications
Current rectal therapy
14 of 60
23.3
Current steroids
24 of 60
40.0
Current oral 5-ASA’s
51 of 60
85.0
Current thiopurines
15 of 60
25.0
Current infliximab
4 of 60
6.7
Current inpatient
Yes
8
13.3
No
52
86.7
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Table 2
Importance of symptom domains (n=28) based on criteria to determine
ulcerative colitis symptom domains that are frequently present during flares and
responsive to changes in disease activity.
Infrequent or
Symptoms that are Frequent and
Unresponsive
Responsive to Change (n=13)
Symptoms (n=15)
Anorexia
Erythema nodosum
Pyoderma
Loose stools (consistency)
Symptom
gangrenosum
Stool blood
Domains
Eye redness / pain
Urgency
Derived from
Fever
Frequency
Common
Use of anti-diarrheals
Nighttime bowel movements
Indices*
Incontinence
Abdominal pain
Nausea
Cramping
Joint pain
Stool mucus
Tenesmus
Difficulty telling liquid or gas from
Symptom
Abdominal distention
solid stool before evacuation
Domains
Lightheadedness
Rapid post-prandial bowel
Derived from
Mouth ulcers
movements
Focus
Insomnia
Loud bowel sounds
Groups+
Low back pain
Flatulence
Fatigue
*Symptom domains derived from common indices (Truelove and Witts, St.
Mark’s Index, CAI, SCCAI, UCSS, Mayo, and UCDAI).
+
Symptom domains identified in focus groups and not found on commonly
used indices
Notes: Symptoms Present and Responsive to Change are those that fit the
criteria of an important symptom domain as defined in Figure 1. Uncommon or
Unresponsive Symptoms are those that do not fulfill criteria of an important
symptom domain.
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28

Symptom Domains Obtained from Common
Disease Activity Indices (N=16)
Frequency
Urgency
Loose Stools
Night bowel movements
Abdominal pain
Anorexia
Erythema Nodosum
Pyoderma Gangrenosum

Eye Pain/Redness
Fever
Anti-diarreheal use
Inconsistence
Nausea
Cramping
Joint Pain

Novel Symptom Domains Obtained from UC
Patients Focus Groups (N=12)
Abdominal distention
Flatulence
Stool mucus
Tenesmus
Lightheadedness
Mouth Ulcers
Fatigue
Sleeplessness
Loud bowel sounds
Low back pain
Rapid bowel movements after eating
Inability to differentiate liquid or gas from solid
when rectal urgency occurs

Evaluate 28 Symptom Domains
with 100 point Visual Analog Scale
Ratings for 3 Criteria
1.
2.
3.

Occurs During Flares
Improves with Therapy
Absent During Remission

Determine whether each symptom domain is important:
defined as when all 3 medians VAS scores are significantly
greater than 50 (2 sided p > 0.05) by the sign test.
Meets Criteria
Important Symptom Domains:
Frequent and Responsive

Does Not Meets Criteria
Non-Important Symptom Domains:
Infrequent or Unresponsive

Figure 1. Flow diagram of 28 symptom domains in Q\questionnaire and criteria
for determining important symptom domains.
Note: Sixteen symptom domains were included from commonly used indices of
ulcerative colitis disease activity (Truelove and Witts, St. Mark’s Index, CAI,
SCCAI, UCSS, Mayo, and UCDAI), and twelve novel symptom domains were
included from previously conducted focus group input (Waljee et al., 2007). The
questionnaire required ratings of the three criteria listed on a 100 mm VAS scale
for each of the 28 symptom domains. Symptom domains were determined to be
either important or non-important for evaluation of disease activity based on
significance of the sign test.
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(a) Do you have this symptom (loose stools) when you have flares of ulcerative
colitis?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
Never occurs

Sometime occurs

10
Always occurs

(b) Does this symptom improve after you start an effective therapy?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never improves
Sometime improves
Always improves
(c) Is this symptom present when your disease is under good control (in
remission)?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never present
Sometime present
Always present
Figure 2. Visual analogue scale used on questionnaire for assessing each of
three endpoints for all 28 symptom domains.
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Figure 3. Visual analogue scale ratings of the three criteria.
Figure 3a. A box plot of the VAS ratings of symptoms present during flares for
the 28 symptom domains is presented.
Note: Each box bounds the region from the 25th to 75th percentile of responses.
The vertical line in each box is the median. Lines connect the boxes to the next
observation beyond the box and the dots represent remaining outliers. The
vertical line at VAS=50 signifies the a priori cutoff value for significantly frequent
symptoms during flare. The symptoms presented in dark gray boxes are those
that met all 3 criteria for symptom importance.
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Figure 3b. A similar box plot is presented in the same format for the symptoms
that improve during therapy.
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Figure 3c. A similar box plot is presented in the same format for the symptoms
that are absent during remission.
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Figure 4. Examples of symptom domains that meet or do not meet criteria for a
common symptom with good dynamic range.
Figure 4a. Dotplot of a symptom domain, stool mucus, which meets criteria

for an important symptom (one that is frequent with good dynamic range).
Note: VAS ratings are from the 100 mm scale. Each dot represents one
individual’s response. The horizontal lines on the graphs are as follows: 25 is the
25th percentile, M is the median, and 75 is the 75th percentile. The horizontal line
at VAS=50 signifies the a priori cutoff value for important symptoms.
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Figure 4b. Dotplot of a symptom domain, anorexia, which did not meet the
criteria for an important symptom (one that is frequent with good dynamic range).
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Appendix A: Sample Survey Form
Ulcerative Colitis Symptom Domains Survey
This questionnaire is designed to help us find out what symptoms change when people
with UC start a treatment that is effective.
This will help us determine the best way to measure whether new treatments are
effective.
Each page will present 3 questions about one symptom.
Each symptom has been suggested as a marker of ulcerative colitis disease activity by
patients in focus groups.
You may have similar symptoms of ulcerative colitis, or you may not have these
symptoms at all. We are interested in finding out more about your experience of
ulcerative colitis.
Please answer each question on a 1-10 scale by marking a single vertical line through the
scale as illustrated below:
(a) Do you have this symptom when you have flares of ulcerative colitis?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never occurs
Sometimes occurs
Always occurs
Please do NOT skip questions – if a question seems odd or confusing, please ask the
person who gave you this questionnaire for an explanation.
Subject ID#

______

Initials

______

Date

______
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(1) When some people with ulcerative colitis have a flare of disease, their stools often
become loose or watery. When they start a treatment for ulcerative colitis that works,
they often notice that their stools become more solid.

(a) Do you have this symptom (loose stools) when you have flares of ulcerative colitis?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never occurs
Sometimes occurs
Always occurs

(b) Does this symptom improve after you start an effective therapy?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never improves
Sometimes improves
Always improves
(c) Is this symptom present when your disease is under good control (in remission)?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never present
Sometimes present
Always present
Free response area: Tell us anything we should know about loose stools in UC.
Does it only occur with severe flares? Only in mild flares?
Does it come on early in flares, or only later on?
Does effective treatment clear this up early, or only after a while?
How should we measure this? Number, amount, percentage, or frequency?
Please tell us about your experience with this symptom. Feel free to continue on the back.
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Please answer each question on a 1-10 scale with a single vertical line.

(2) When some people with ulcerative colitis have a flare of disease, their stools often
contain blood. When they start a treatment for ulcerative colitis that works, they often
notice that the blood goes away.

(a) Do you have this symptom (bloody stools) when you have flares of ulcerative colitis?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never occurs
Sometimes occurs
Always occurs

(b) Does this symptom improve after you start an effective therapy?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never improves
Sometimes improves
Always improves
(c) Is this symptom present when your disease is under good control (in remission)?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never present
Sometimes present
Always present
Free response area: Tell us anything we should know about bloody stools in UC.
Does it only occur with severe flares? Only in mild flares?
Does it come on early in flares, or only later on?
Does effective treatment clear this up early, or only after a while?
How should we measure this? Number, amount, percentage, or frequency?
Please tell us about your experience with this symptom. Feel free to continue on the back.
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Please answer each question on a 1-10 scale with a single vertical line:

(3) When some people with ulcerative colitis have a flare of disease, their stools often
contain mucus. When they start a treatment for ulcerative colitis that works, they
often notice that the mucus goes away.

(a) Do you have this symptom (mucus in stools) when you have flares of ulcerative
colitis?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never occurs
Sometimes occurs
Always occurs

(b) Does this symptom improve after you start an effective therapy?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never improves
Sometimes improves
Always improves
(c) Is this symptom present when your disease is under good control (in remission)?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never present
Sometimes present
Always present
Free response area: Tell us anything we should know about mucus in stools in UC.
Does it only occur with severe flares? Only in mild flares?
Does it come on early in flares, or only later on?
Does effective treatment clear this up early, or only after a while?
How should we measure this? Number, amount, percentage, or frequency?
Please tell us about your experience with this symptom. Feel free to continue on the back.
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Please answer each question on a 1-10 scale with a single vertical line:

(4) When some people with ulcerative colitis have a flare of disease, they have very
frequent stools. When they start a treatment for ulcerative colitis that works, they
often notice that the frequency of stools goes down.

(a) Do you have this symptom (frequent stools) when you have flares of ulcerative
colitis?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never occurs
Sometimes occurs
Always occurs

(b) Does this symptom improve after you start an effective therapy?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never improves
Sometimes improves
Always improves
(c) Is this symptom present when your disease is under good control (in remission)?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never present
Sometimes present
Always present
Free response area: Tell us anything we should know about frequent stools in UC.
Does it only occur with severe flares? Only in mild flares?
Does it come on early in flares, or only later on?
Does effective treatment clear this up early, or only after a while?
How should we measure this? Number, amount, percentage, or frequency?
Please tell us about your experience with this symptom. Feel free to continue on the back.
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Please answer each question on a 1-10 scale with a single vertical line:

(5) When some people with ulcerative colitis have a flare of disease, they often become
very tired. When they start a treatment for ulcerative colitis that works, they often
notice that the tiredness improves.

(a) Do you have this symptom (tiredness) when you have flares of ulcerative colitis?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never occurs
Sometimes occurs
Always occurs

(b) Does this symptom improve after you start an effective therapy?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never improves
Sometimes improves
Always improves
(c) Is this symptom present when your disease is under good control (in remission)?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never present
Sometimes present
Always present
Free response area: Tell us anything we should know about tiredness with UC.
Does it only occur with severe flares? Only in mild flares?
Does it come on early in flares, or only later on?
Does effective treatment clear this up early, or only after a while?
How should we measure this? Number, amount, percentage, or frequency?
Please tell us about your experience with this symptom. Feel free to continue on the back.
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Please answer each question on a 1-10 scale with a single number.

(6) When some people with ulcerative colitis have a flare of disease, they often have to
rush to the toilet (urgency). When they start a treatment for ulcerative colitis that
works, they often notice that the urgency goes away.

(a) Do you have this symptom (urgency) when you have flares of ulcerative colitis?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never occurs
Sometimes occurs
Always occurs

(b) Does this symptom improve after you start an effective therapy?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never improves
Sometimes improves
Always improves
(c) Is this symptom present when your disease is under good control (in remission)?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never present
Sometimes present
Always present
Free response area: Tell us anything we should know about urgency with UC.
Does it only occur with severe flares? Only in mild flares?
Does it come on early in flares, or only later on?
Does effective treatment clear this up early, or only after a while?
How should we measure this? Number, amount, percentage, or frequency?
Please tell us about your experience with this symptom. Feel free to continue on the back.
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Please answer each question on a 1-10 scale with a single vertical line:

(7) When some people with ulcerative colitis have a flare of disease, they often go to the
bathroom, then have to go again rapidly in seconds to minutes (tenesmus). When they
start a treatment for ulcerative colitis that works, they often notice that they can go
once and not have to go again.

(a) Do you have this symptom (tenesmus) when you have flares of ulcerative colitis?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never occurs
Sometimes occurs
Always occurs

(b) Does this symptom improve after you start an effective therapy?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never improves
Sometimes improves
Always improves
(c) Is this symptom present when your disease is under good control (in remission)?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never present
Sometimes present
Always present
Free response area: Tell us anything we should know about tenesmus with UC.
Does it only occur with severe flares? Only in mild flares?
Does it come on early in flares, or only later on?
Does effective treatment clear this up early, or only after a while?
How should we measure this? Number, amount, percentage, or frequency?
Please tell us about your experience with this symptom. Feel free to continue on the back.
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Please answer each question on a 1-10 scale with a single vertical line:

(8) When some people with ulcerative colitis have a flare of disease, they notice that they
have a lot more gas (flatulence). When they start a treatment for ulcerative colitis that
works, they often notice that they have less gas.

(a) Do you have this symptom (flatulence) when you have flares of ulcerative colitis?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never occurs
Sometimes occurs
Always occurs

(b) Does this symptom improve after you start an effective therapy?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never improves
Sometimes improves
Always improves
(c) Is this symptom present when your disease is under good control (in remission)?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never present
Sometimes present
Always present
Free response area: Tell us anything we should know about flatulence with UC.
Does it only occur with severe flares? Only in mild flares?
Does it come on early in flares, or only later on?
Does effective treatment clear this up early, or only after a while?
How should we measure this? Number, amount, percentage, or frequency?
Please tell us about your experience with this symptom. Feel free to continue on the back.
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Please answer each question on a 1-10 scale with a single vertical line:

(9) When some people with ulcerative colitis have a flare of disease, they notice that they
have trouble telling whether they are going to pass just gas or something liquid or
solid, so they have to go to the toilet every time to be safe. When they start a
treatment for ulcerative colitis that works, they often notice that they can tell the
difference, and don’t have to go to the toilet all the time.

(a) Do you have this symptom (difficulty telling if you have gas or stool) when you have
flares of ulcerative colitis?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never occurs
Sometimes occurs
Always occurs

(b) Does this symptom improve after you start an effective therapy?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never improves
Sometimes improves
Always improves
(c) Is this symptom present when your disease is under good control (in remission)?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never present
Sometimes present
Always present
Free response area: Tell us anything we should know about this symptom with UC.
Does it only occur with severe flares? Only in mild flares?
Does it come on early in flares, or only later on?
Does effective treatment clear this up early, or only after a while?
How should we measure this? Number, amount, percentage, or frequency?
Please tell us about your experience with this symptom. Feel free to continue on the back.
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Please answer each question on a 1-10 scale with a single number.

(10) When some people with ulcerative colitis have a flare of disease, they notice that
they get painful cramps in their rectum with bowel movements. When they start a
treatment for ulcerative colitis that works, they often notice that they can have bowel
movements without this cramping pain in the rectum.

(a) Do you have this symptom (rectal cramps) when you have flares of ulcerative colitis?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never occurs
Sometimes occurs
Always occurs

(b) Does this symptom improve after you start an effective therapy?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never improves
Sometimes improves
Always improves
(c) Is this symptom present when your disease is under good control (in remission)?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never present
Sometimes present
Always present
Free response area: Tell us anything we should know about rectal cramps with UC.
Does it only occur with severe flares? Only in mild flares?
Does it come on early in flares, or only later on?
Does effective treatment clear this up early, or only after a while?
How should we measure this? Number, amount, percentage, or frequency?
Please tell us about your experience with this symptom. Feel free to continue on the back.
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Please answer each question on a 1-10 scale with a single number.

(11) When some people with ulcerative colitis have a flare of disease, they notice that
their abdomen gets more distended and sticks out. When they start a treatment for
ulcerative colitis that works, they often notice that this improves.

(a) Do you have this symptom (distention) when you have flares of ulcerative colitis?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never occurs
Sometimes occurs
Always occurs

(b) Does this symptom improve after you start an effective therapy?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never improves
Sometimes improves
Always improves
(c) Is this symptom present when your disease is under good control (in remission)?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never present
Sometimes present
Always present
Free response area: Tell us anything we should know about distention with UC.
Does it only occur with severe flares? Only in mild flares?
Does it come on early in flares, or only later on?
Does effective treatment clear this up early, or only after a while?
How should we measure this? Number, amount, percentage, or frequency?
Please tell us about your experience with this symptom. Feel free to continue on the back.
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Please answer each question on a 1-10 scale with a single number.

(12) When some people with ulcerative colitis have a flare of disease, they notice that
they get pain in the lower back. When they start a treatment for ulcerative colitis that
works, they often notice that this improves.

(a) Do you have this symptom (low back pain) when you have flares of ulcerative colitis?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never occurs
Sometimes occurs
Always occurs

(b) Does this symptom improve after you start an effective therapy?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never improves
Sometimes improves
Always improves
(c) Is this symptom present when your disease is under good control (in remission)?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never present
Sometimes present
Always present
Free response area: Tell us anything we should know about low back pain with UC.
Does it only occur with severe flares? Only in mild flares?
Does it come on early in flares, or only later on?
Does effective treatment clear this up early, or only after a while?
How should we measure this? Number, amount, percentage, or frequency?
Please tell us about your experience with this symptom. Feel free to continue on the back.
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Please answer each question on a 1-10 scale with a single number.

(13) When some people with ulcerative colitis have a flare of disease, they notice that
they get loud digestive sounds from the abdomen. When they start a treatment for
ulcerative colitis that works, they often notice that these sounds decrease.

(a) Do you have this symptom (loud abdominal sounds) when you have flares of
ulcerative colitis?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never occurs
Sometimes occurs
Always occurs

(b) Does this symptom improve after you start an effective therapy?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never improves
Sometimes improves
Always improves
(c) Is this symptom present when your disease is under good control (in remission)?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never present
Sometimes present
Always present
Free response area: Tell us anything we should know about loud abdominal sounds with
UC.
Does it only occur with severe flares? Only in mild flares?
Does it come on early in flares, or only later on?
Does effective treatment clear this up early, or only after a while?
How should we measure this? Number, amount, percentage, or frequency?
Please tell us about your experience with this symptom. Feel free to continue on the back.
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Please answer each question on a 1-10 scale with a single vertical line:

(14) When some people with ulcerative colitis have a flare of disease, they notice that
they have a lot of nausea and feel like they need to vomit. When they start a treatment for
ulcerative colitis that works, they often notice that the nausea gets better.

(a) Do you have this symptom (nausea) when you have flares of ulcerative colitis?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never occurs
Sometimes occurs
Always occurs

(b) Does this symptom improve after you start an effective therapy?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never improves
Sometimes improves
Always improves
(c) Is this symptom present when your disease is under good control (in remission)?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never present
Sometimes present
Always present
Free response area: Tell us anything we should know about nausea with UC.
Does it only occur with severe flares? Only in mild flares?
Does it come on early in flares, or only later on?
Does effective treatment clear this up early, or only after a while?
How should we measure this? Number, amount, percentage, or frequency?
Please tell us about your experience with this symptom. Feel free to continue on the back.

50

VALIDUC-DOMAINS

Please answer each question on a 1-10 scale with a single vertical line:

(15) When some people with ulcerative colitis have a flare of disease, they notice that
they lose their appetite. When they start a treatment for ulcerative colitis that works, they
often notice that their appetite gets better.

(a) Do you have this symptom (loss of appetite) when you have flares of ulcerative
colitis?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never occurs
Sometimes occurs
Always occurs

(b) Does this symptom improve after you start an effective therapy?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never improves
Sometimes improves
Always improves
(c) Is this symptom present when your disease is under good control (in remission)?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never present
Sometimes present
Always present
Free response area: Tell us anything we should know about loss of appetite with UC.
Does it only occur with severe flares? Only in mild flares?
Does it come on early in flares, or only later on?
Does effective treatment clear this up early, or only after a while?
How should we measure this? Number, amount, percentage, or frequency?
Please tell us about your experience with this symptom. Feel free to continue on the back.
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Please answer each question on a 1-10 scale with a single vertical line:

(16) When some people with ulcerative colitis have a flare of disease, they notice that
they have a lot of pain in the abdomen. When they start a treatment for ulcerative colitis
that works, they often notice that the pain in the abdomen gets better.

(a) Do you have this symptom (abdominal pain) when you have flares of ulcerative
colitis?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never occurs
Sometimes occurs
Always occurs

(b) Does this symptom improve after you start an effective therapy?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never improves
Sometimes improves
Always improves
(c) Is this symptom present when your disease is under good control (in remission)?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never present
Sometimes present
Always present
Free response area: Tell us anything we should know about abdominal pain with UC.
Does it only occur with severe flares? Only in mild flares?
Does it come on early in flares, or only later on?
Does effective treatment clear this up early, or only after a while?
How should we measure this? Number, amount, percentage, or frequency?
Please tell us about your experience with this symptom. Feel free to continue on the back.
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Please answer each question on a 1-10 scale with a single vertical line:

(17) When some people with ulcerative colitis have a flare of disease, they notice that
their joints hurt. When they start a treatment for ulcerative colitis that works, they often
notice that the joint pain gets better.

(a) Do you have this symptom (joint pain) when you have flares of ulcerative colitis?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never occurs
Sometimes occurs
Always occurs

(b) Does this symptom improve after you start an effective therapy?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never improves
Sometimes improves
Always improves
(c) Is this symptom present when your disease is under good control (in remission)?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never present
Sometimes present
Always present
Free response area: Tell us anything we should know about joint pain with UC.
Does it only occur with severe flares? Only in mild flares?
Does it come on early in flares, or only later on?
Does effective treatment clear this up early, or only after a while?
How should we measure this? Number, amount, percentage, or frequency?
Please tell us about your experience with this symptom. Feel free to continue on the back.
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Please answer each question on a 1-10 scale with a single vertical line:

(18) When some people with ulcerative colitis have a flare of disease, they notice that
they get ulcers in their mouth. When they start a treatment for ulcerative colitis that
works, they often notice that the mouth ulcers get better.

(a) Do you have this symptom (mouth ulcers) when you have flares of ulcerative colitis?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never occurs
Sometimes occurs
Always occurs

(b) Does this symptom improve after you start an effective therapy?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never improves
Sometimes improves
Always improves
(c) Is this symptom present when your disease is under good control (in remission)?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never present
Sometimes present
Always present
Free response area: Tell us anything we should know about mouth ulcers with UC.
Does it only occur with severe flares? Only in mild flares?
Does it come on early in flares, or only later on?
Does effective treatment clear this up early, or only after a while?
How should we measure this? Number, amount, percentage, or frequency?
Please tell us about your experience with this symptom. Feel free to continue on the back.
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Please answer each question on a 1-10 scale with a single vertical line:

(19) When some people with ulcerative colitis have a flare of disease, they notice that
they get redness and pain in the eyes. When they start a treatment for ulcerative colitis
that works, they often notice that their eyes get better.

(a) Do you have this symptom (eye pain and redness) when you have flares of ulcerative
colitis?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never occurs
Sometimes occurs
Always occurs

(b) Does this symptom improve after you start an effective therapy?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never improves
Sometimes improves
Always improves
(c) Is this symptom present when your disease is under good control (in remission)?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never present
Sometimes present
Always present
Free response area: Tell us anything we should know about eye pain and redness with
UC.
Does it only occur with severe flares? Only in mild flares?
Does it come on early in flares, or only later on?
Does effective treatment clear this up early, or only after a while?
How should we measure this? Number, amount, percentage, or frequency?
Please tell us about your experience with this symptom. Feel free to continue on the back.
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Please answer each question on a 1-10 scale with a single vertical line:

(20) When some people with ulcerative colitis have a flare of disease, they notice that
they get have a lot of bowel movements during the night that can interfere with sleep.
When they start a treatment for ulcerative colitis that works, they often notice that they
have fewer bowel movements at night.

(a) Do you have this symptom (night BMs) when you have flares of ulcerative colitis?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never occurs
Sometimes occurs
Always occurs

(b) Does this symptom improve after you start an effective therapy?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never improves
Sometimes improves
Always improves
(c) Is this symptom present when your disease is under good control (in remission)?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never present
Sometimes present
Always present
Free response area: Tell us anything we should know about night BMs with UC.
Does it only occur with severe flares? Only in mild flares?
Does it come on early in flares, or only later on?
Does effective treatment clear this up early, or only after a while?
How should we measure this? Number, amount, percentage, or frequency?
Please tell us about your experience with this symptom. Feel free to continue on the back.
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Please answer each question on a 1-10 scale with a single vertical line:

(21) When some people with ulcerative colitis have a flare of disease, they notice that
they have fever. When they start a treatment for ulcerative colitis that works, they often
notice that the fever gets better.

(a) Do you have this symptom (fever) when you have flares of ulcerative colitis?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never occurs
Sometimes occurs
Always occurs

(b) Does this symptom improve after you start an effective therapy?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never improves
Sometimes improves
Always improves
(c) Is this symptom present when your disease is under good control (in remission)?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never present
Sometimes present
Always present
Free response area: Tell us anything we should know about fever with UC.
Does it only occur with severe flares? Only in mild flares?
Does it come on early in flares, or only later on?
Does effective treatment clear this up early, or only after a while?
How should we measure this? Number, amount, percentage, or frequency?
Please tell us about your experience with this symptom. Feel free to continue on the back.
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Please answer each question on a 1-10 scale with a single vertical line:

(22) When some people with ulcerative colitis have a flare of disease, they notice that
they have accidents and lose control of their stool (incontinence). When they start a
treatment for ulcerative colitis that works, they often notice that the incontinence gets
better.

(a) Do you have this symptom (incontinence) when you have flares of ulcerative colitis?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never occurs
Sometimes occurs
Always occurs

(b) Does this symptom improve after you start an effective therapy?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never improves
Sometimes improves
Always improves
(c) Is this symptom present when your disease is under good control (in remission)?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never present
Sometimes present
Always present
Free response area: Tell us anything we should know about incontinence with UC.
Does it only occur with severe flares? Only in mild flares?
Does it come on early in flares, or only later on?
Does effective treatment clear this up early, or only after a while?
How should we measure this? Number, amount, percentage, or frequency?
Please tell us about your experience with this symptom. Feel free to continue on the back.
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Please answer each question on a 1-10 scale with a single vertical line:

(23) When some people with ulcerative colitis have a flare of disease, they notice that
they need to use anti-diarrheal medicines. When they start a treatment for ulcerative
colitis that works, they often notice that they need a lot less or no anti-diarrheal
medicines.

(a) Do you increase your use of anti-diarrheal medications when you have flares of
ulcerative colitis?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never occurs
Sometimes occurs
Always occurs

(b) Do you decrease your use of anti-diarrheal medications after you start an effective
therapy?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never improves
Sometimes improves
Always improves
(c) Do you use anti-diarrheal medications when your disease is under good control (in
remission)?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never present
Sometimes present
Always present
Free response area: Tell us anything we should know about anti-diarrheal medication use
with UC.
Does it only occur with severe flares? Only in mild flares?
Does it come on early in flares, or only later on?
Does effective treatment clear this up early, or only after a while?
How should we measure this? Number, amount, percentage, or frequency?
Please tell us about your experience with this symptom. Feel free to continue on the back.
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Please answer each question on a 1-10 scale with a single vertical line:

(24) When some people with ulcerative colitis have a flare of disease, they notice that
eating even a small amount stimulates almost immediate bowl movements. When they
start a treatment for ulcerative colitis that works, they often notice that they can eat and
not immediately have a bowel movement.

(a) Do you have this symptom (rapid BMs after eating) when you have flares of
ulcerative colitis?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never occurs
Sometimes occurs
Always occurs

(b) Does this symptom improve after you start an effective therapy?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never improves
Sometimes improves
Always improves
(c) Is this symptom present when your disease is under good control (in remission)?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never present
Sometimes present
Always present
Free response area: Tell us anything we should know about rapid bowel movements after
eating with UC.
Does it only occur with severe flares? Only in mild flares?
Does it come on early in flares, or only later on?
Does effective treatment clear this up early, or only after a while?
How should we measure this? Number, amount, percentage, or frequency?
Please tell us about your experience with this symptom. Feel free to continue on the back.
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Please answer each question on a 1-10 scale with a single vertical line:

(25) When some people with ulcerative colitis have a flare of disease, they notice that
they feel lightheaded. When they start a treatment for ulcerative colitis that works, they
often notice that the lightheadedness gets better.

(a) Do you have this symptom (lightheadedness) when you have flares of ulcerative
colitis?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never occurs
Sometimes occurs
Always occurs

(b) Does this symptom improve after you start an effective therapy?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never improves
Sometimes improves
Always improves
(c) Is this symptom present when your disease is under good control (in remission)?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never present
Sometimes present
Always present
Free response area: Tell us anything we should know about lightheadedness with UC.
Does it only occur with severe flares? Only in mild flares?
Does it come on early in flares, or only later on?
Does effective treatment clear this up early, or only after a while?
How should we measure this? Number, amount, percentage, or frequency?
Please tell us about your experience with this symptom. Feel free to continue on the back.
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Please answer each question on a 1-10 scale with a single vertical line:

(26) When some people with ulcerative colitis have a flare of disease, they notice that
they sleep less. When they start a treatment for ulcerative colitis that works, they often
notice that they get more sleep.

(a) Do you have this symptom (loss of sleep) when you have flares of ulcerative colitis?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never occurs
Sometimes occurs
Always occurs

(b) Does this symptom improve after you start an effective therapy?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never improves
Sometimes improves
Always improves
(c) Is this symptom present when your disease is under good control (in remission)?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never present
Sometimes present
Always present
Free response area: Tell us anything we should know about loss of sleep with UC.
Does it only occur with severe flares? Only in mild flares?
Does it come on early in flares, or only later on?
Does effective treatment clear this up early, or only after a while?
How should we measure this? Number, amount, percentage, or frequency?
Please tell us about your experience with this symptom. Feel free to continue on the back.
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Please answer each question on a 1-10 scale with a single vertical line:

(27) When some people with ulcerative colitis have a flare of disease, they notice that
they have raised, red, tender bumps on their skin, usually on the shins (erythema
nodosum). When they start a treatment for ulcerative colitis that works, they often notice
that these bumps go away.

(a) Do you have this symptom (red tender bumps on the skin) when you have flares of
ulcerative colitis?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never occurs
Sometimes occurs
Always occurs

(b) Does this symptom improve after you start an effective therapy?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never improves
Sometimes improves
Always improves
(c) Is this symptom present when your disease is under good control (in remission)?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never present
Sometimes present
Always present
Free response area: Tell us anything we should know about loss of red tender bumps on
the skin with UC.
Does it only occur with severe flares? Only in mild flares?
Does it come on early in flares, or only later on?
Does effective treatment clear this up early, or only after a while?
How should we measure this? Number, amount, percentage, or frequency?
Please tell us about your experience with this symptom. Feel free to continue on the back.
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Please answer each question on a 1-10 scale with a single vertical line:

(28) When some people with ulcerative colitis have a flare of disease, they notice that
they get red pimple-like areas on the skin that break down and turn into skin ulcers
(pyoderma gangrenosum). When they start a treatment for ulcerative colitis that works,
they often notice that these ulcers get better.

(a) Do you have this symptom (skin ulcers) when you have flares of ulcerative colitis?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never occurs
Sometimes occurs
Always occurs

(b) Does this symptom improve after you start an effective therapy?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never improves
Sometimes improves
Always improves
(c) Is this symptom present when your disease is under good control (in remission)?
Rate this on the 1-10 scale as illustrated below with a single vertical line:
1
10
Never present
Sometimes present
Always present
Free response area: Tell us anything we should know about skin ulcers with UC.
Does it only occur with severe flares? Only in mild flares?
Does it come on early in flares, or only later on?
Does effective treatment clear this up early, or only after a while?
How should we measure this? Number, amount, percentage, or frequency?
Please tell us about your experience with this symptom. Feel free to continue on the back.
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Appendix B: Sample Informed Consent

University of Michigan - Consent To Be Part of a Research Study
Information About This Form
You may be eligible to take part in a research study. This form gives you important
information about the study. It describes the purpose of the study, and the risks and
possible benefits of participating in the study.
Please take time to review this information carefully. After you have finished, you should
talk to the researchers about the study and ask them any questions you have. You may
also wish to talk to others (for example, your friends, family, or other doctors) about your
participation in this study. If you decide to take part in the study, you will be asked to
sign this form. Before you sign this form, be sure you understand what the study is about,
including the risks and possible benefits to you.
1. General Information About This Study AND the RESEARCHERS
1.1 Study title:
ValidUC2 Phase 1A: Domains
1.2 Company or agency sponsoring the study:
Crohns and Colitis Foundation of America
Names, degrees, and affiliations of the researchers conducting the study:
Peter Higgins, M.D., Ph.D.- Assistant Professor in Gastroenterology, Internal Medicine,
Division of Gastroenterology, University of Michigan.
Tahira Khan, MBBS, Division of Gastroenterology, University of Michigan.
Akbar Waljee, MD, Department of Internal Medicine, University of Michigan
Joel Joyce, Division of Gastroenterology, University of Michigan
2. PURPOSE OF THIS STUDY
2.1 Study purpose:
To identify disease activity symptom domains in ulcerative colitis that:
are related to patients’ experience of ulcerative colitis
change when their disease is active vs. when inactive
occur reproducibly when they have a flare of disease
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3. Information About STUDY participants (SUBJECTS)
Taking part in this study is completely voluntary. You do not have to participate if you
don't want to. You may also leave the study at any time. If you leave the study before it
is finished, there will be no penalty to you, and you will not lose any benefits to which
you are otherwise entitled.
3.1 Who can take part in this study?
Inclusion criteria:
Patients have to have ulcerative colitis and have not had their colon removed by surgery.
Patients who are between 18-75 years of age who are willing and able to fill out a survey
form.
Patients primary GI physician must agree that they are appropriate for this study.
Exclusion Criteria:
Students, employees, or family members of the investigators.
Prisoners.
Subjects not competent to consent for themselves.
Subjects who have previously participated in this phase of the study.
3.2 How many people (subjects) are expected to take part in this study?
100
4. information about study procedures
4.1 What exactly will be done to me in this study? What kinds of research procedures
will I receive if I agree to take part in this study?
If you are interested in participating, you will be interviewed either in your room
(inpatients) or in a consultation room. You will be evaluated to confirm that you meet all
of the eligibility criteria. This consent form will be reviewed with you, and any domains
(A group of interrelated symptoms within a given category) will be answered by the
study staff member. Three copies of the signed consent form will be required.
You will then be provided with a survey form with detailed instructions. You will be
asked to review the domains(A group of interrelated symptoms within a given category),
and evaluate each domain according to three criteria on a 1-10 visual analog scale. We
will also encourage you to write comments, suggestions or edits on the domains
themselves. We expect this evaluation of domains to take approximately 25-45 minutes.
4.2 How much of my time will be needed to take part in this study? When will my
participation in the study be over?
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The time needed for consent process (5-10 minutes) and filling out survey- approximately
25-45 minutes. Your participation will be over as soon as you fill out the survey. Total
time is expected to be 30-55 minutes. This survey will be conducted once only.
5. Information about RISKS and benefits
5.1 What risks will I face by taking part in the study? What will the researchers do to
protect me against these risks?
The known or expected risks are:
The potential risks to you from being in this study are minimal. Confidentiality Risks: are
rare (i.e., approximate incidence < 1%)
All of the patients whose responses are used for the study will be assigned a confidential
identification number. All responses will be coded by this number, and not the patient’s
name or hospital registration number. Identifying information will be placed in a database
along with the unique confidential ID number. The data table containing the unique
identifier and the clinical information are kept in a separate password- protected secure
file.
As with any research study, there may be additional risks that are unknown or
unexpected.
5.2 What happens if I get hurt, become sick, or have other problems as a result of this
research?
The researchers have taken steps to minimize the known or expected risks. However,
you may still experience problems or side effects, even when the researchers are careful
to avoid them. If you believe that you have been harmed, notify the researchers listed in
Section 10 of this form. The University of Michigan will provide first aid or emergency
care. The cost of this first aid or emergency care may be billed to your insurance
company, but if it is not covered by your insurance, the University of Michigan will pay
for it. Additional medical care will be provided if the University determines that it is
responsible to provide such treatment. If you sign this form, you do not give up your
right to seek additional compensation if you are harmed as a result of being in this study.
Please note: It is important that you tell the researchers about any injuries, side effects,
or other problems that you experience during this study. You may also need to tell your
regular doctors.
5.3 If I take part in this study, can I also participate in other studies?

67

VALIDUC-DOMAINS

Being in more than one research study at the same time, or even at different times, may
increase the risks to you. It may also affect the results of the studies. You should not
take part in more than one study without approval from the researchers involved in each
study.
5.4 How could I benefit if I take part in this study? How could others benefit?
You may not receive any personal benefits from being in the study. However, the
information we gain from you may lead to a better way of measuring ulcerative colitis.
This may contribute to the development of new treatments that will improve the
symptoms that matter most to patients
5.5 Will the researchers tell me if they learn of new information that could change my
willingness to stay in this study?
No, this is a one-time survey study and participation in the study will be completed on the
day the survey is filled out.
6. Other options
6.1 If I decide not to take part in this study, what other options do I have?
Whether or not you choose to participate in this study, you will continue your current
care as directed by your primary gastroenterologist.
Your care by your doctor will NOT be affected by whether or not you join the study.
7. ENDING THE STUDY
7.1 If I want to stop participating in the study, what should I do?
You are free to leave the study at any time. If you leave the study before it is finished,
there will be no penalty to you, and you will not lose any benefits to which you may
otherwise be entitled. Your participation in the study will be completed on the day that
the questionnaire will be administered. If there are questions that you do not wish to
answer, they may be left blank. If you choose to inform the investigator why you have
omitted your answer, please feel free to do so.
7.2 Could there be any harm to me if I decide to leave the study before it is finished?
No
7.3 Could the researchers take me out of the study even if I want to continue to
participate?
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The researcher will not ask you to enroll in the study if it is not in your best interest.
There are many reasons why the researchers may need to end your participation in the
study. Some examples are:
The researcher believes that it is not in your best interest to stay in the study.
You become ineligible to participate.
Your condition changes and you need treatment that is not allowed while you are taking
part in the study.
You do not follow instructions from the researchers.
The study is suspended or canceled.
8. Financial Information
8.1 Will taking part in this study cost me anything? Will I or my insurance company be
billed for any costs of the study? If so, which costs? What happens if my insurance does
not cover these costs?
You or your insurance company will NOT be billed for any costs related to the study.
8.2 Will I be paid or given anything for taking part in this study?
Yes, you will be paid $5.00 to cover any parking related costs.
8.3 Who could profit or financially benefit from the study results?
No One
9. confidentiality of subject records and authorization to release your protected health
information
University of Michigan policies require that private information about you be protected.
This is especially true for your personal health information.
On the other hand, sometimes the law allows or requires others to see your information.
The information given below describes how your privacy and the confidentiality of your
research records will be protected in this study.
9.1 How will the researchers protect my privacy?
All the patients whose responses are used for the study will be assigned a unique
identification number. Identifying information will be placed in a database along with the
unique identifier. The data table containing the unique identifier and the clinical
information are kept in a password- protected secure file. No one will have access to this
information except the research staff listed under section 1.3 of this document.
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9.2 What information about me could be seen by the researchers or by other people?
Why? Who might see it?
Signing this form gives the researchers your permission to obtain, use, and share
information about you for this study, and is required in order for you to take part in the
study. Information about you may be obtained from any hospital, doctor, and other
health care provider involved in your care.
Information about you may include information about your health and your medical care
before, during, and after the study, even if that information wasn't collected as part of this
research study. For example:
All records relating to your condition, the treatment you have received, and your response
to the treatment to confirm that you truly have ulcerative colitis.
There are many reasons why information about you may be used or seen by the
researchers or others during this study. Examples include:
The researchers may need the information to make sure you can take part in the study.
University, Food and Drug Administration [FDA], and other government officials may
need the information to make sure that the study is done properly.
Organizations that are funding the study may need the information to make sure that the
study is done properly.
Safety monitors or committees may need the information to make sure that the study is
safe.
If you receive any payments for taking part in this study, the University of Michigan
accounting department may need your name, address, social security number, payment
amount, and related information for tax reporting purposes.
The results of this study could be published in an article, but would not include any
information that would let others know who you are.
9.3 What happens to information about me after the study is over or if I cancel my
permission?
As a rule, the researchers will not continue to use or disclose information about you, but
will keep it secure until it is destroyed. Sometimes, it may be necessary for information
about you to continue to be used or disclosed, even after you have canceled your
permission or the study is over. Examples of reasons for this include:
To avoid losing study results that have already included your information
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To provide limited information for research, education, or other activities (This
information would not include your name, social security number, or anything else that
could let others know who you are.)
To help University and government officials make sure that the study was conducted
properly
As long as your information is kept within the University of Michigan Health System, it
is protected by the Health System’s privacy policies. For more information about these
policies, ask for a copy of the University of Michigan Notice of Privacy Practices. This
information is also available on the web at http://www.med.umich.edu/hipaa/npp.htm.
Note that once your information has been shared with others as described under Question
9.2, it may no longer be protected by the privacy regulations of the federal Health
Insurance Portability and Accountability Act of 1996 (HIPAA).
9.4 When does my permission expire?
Your permission expires at the end of the study, unless you cancel it sooner. You may
cancel your permission at any time by writing to the researchers listed in Section 10
"Contact Information" (below).
10. Contact Information
10.1 Who can I contact about this study?
Please contact the researchers listed below to:
Obtain more information about the study
Ask a question about the study procedures or treatments
Report an illness, injury, or other problem (you may also need to tell your regular
doctors)
Leave the study before it is finished
Express a concern about the study
Principal Investigator: Peter D Higgins, M.D. Ph.D.
Mailing Address: 6520 MSRB I, Ann Arbor, MI, 48109
Telephone: 734-763-7278
Study Investigator: Tahira Khan, M.B.B.S.
Mailing Address: 6520 MSRB I, Ann Arbor, MI, 48109
Telephone: 734-615-2457
You may also express a concern about a study by contacting the Institutional Review
Board listed below, or by calling the University of Michigan Compliance Help Line at 1888-296-2481.
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University of Michigan Medical School Institutional Review Board (IRBMED)
Argus I
517 W. William
Ann Arbor, MI 48103-4943
Telephone: 734-763-4768
Fax: 734-615-1622
e-mail: irbmed@umich.edu
If you are concerned about a possible violation of your privacy, contact the University of
Michigan Health System Privacy Officer at 1-888-296-2481.
When you call or write about a concern, please provide as much information as possible,
including the name of the researcher, the IRBMED number (at the top of this form), and
details about the problem. This will help University officials to look into your concern.
When reporting a concern, you do not have to give your name unless you want to.
11. record of Information provided
11.1 What documents will be given to me?
Your signature in the next section means that you have received copies of all of the
following documents:
This "Consent to be Part of a Research Study" document. (Note: In addition to the
copy you receive, copies of this document will be stored in a separate confidential
research file and may be entered into your regular University of Michigan medical
record.)
Other (specify):______________________________________
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12. SIGNATURES
Research Subject:
I understand the information printed on this form. I have discussed this study, its risks and

____________________

.
potential benefits, and my other choices with
My questions so far have been answered. I understand that if I have more questions or
concerns about the study or my participation as a research subject, I may contact one of the
people listed in Section 10 (above). I understand that I will receive a copy of this form at the
time I sign it and later upon request. I understand that if my ability to consent for myself
changes, either I or my legal representative may be asked to re-consent prior to my continued
participation in this study.

Signature of Subject:

Date: ___________________

Name (Print legal name): _________________________________________
Patient ID: ______________

Date of Birth: ________________

Principal Investigator (or Designee):
I have given this research subject (or his/her legally authorized representative, if applicable)
information about this study that I believe is accurate and complete. The subject has indicated
that he or she understands the nature of the study and the risks and benefits of participating.
Name:

_

Title: ________________________________

Signature:

Date of Signature: ______________________

Signature:

Date of Signature:_______________________
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Demographic Information Case Report Form for Domains Survey
Subject Name: _____________________
Subject Initials:

_________________

CPI # :

_________________

Subject Study ID #:

___________

Check only one box:
Male
American Indian or Alaskan Native:
Asian or Pacific Islander
Black, not of Hispanic origin:
Hispanic:
White, not of Hispanic origin:
Other

Female

